Biogen | BIIB - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.52B 258M 2026-09
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Bayer EUR 10.04B 168M 2026-06
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 13.04B 9.09B 2026-09
Incyte USD 5.64B 4.67B 2026-09
Merck USD 10.75B 5.02B 2026-09
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novartis USD 9.88B 325M 2026-09
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 598M 2026-09
Sanofi EUR 9.92B 941M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09